Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 11/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17699005 | 1.00 | HCAR2 (0.59) | HCAR2KEAP1NFE2L2ALDH1A1KDM4E | |
| SCHEMBL15824042 | 0.93 | HCAR2 (0.52) | HCAR2KEAP1NFE2L2TDP1GFPT1 | |
| SCHEMBL15824044 | 0.93 | HCAR2 (0.52) | HCAR2KEAP1NFE2L2TDP1GFPT1 | |
| SCHEMBL15824045 | 0.93 | HCAR2 (0.52) | HCAR2KEAP1NFE2L2TDP1GFPT1 | |
| SCHEMBL19048786 | 0.91 | HCAR2 (0.52) | HCAR2ATM | |
| SCHEMBL18475972 | 0.85 | HCAR2 (0.42) | HCAR2KEAP1NFE2L2ALDH1A1KDM4E | |
| SCHEMBL17048419 | 0.84 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2 | |
| SCHEMBL17048322 | 0.84 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2 | |
| SCHEMBL17955615 | 0.84 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MAPTTDP1 | |
| SCHEMBL17048418 | 0.84 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212626-B1 | THREE COMPONENT SALTS OF FUMARIC ACID MONOMETHYL ESTER WITH PIPERAZINE OR ETHYLENE DIAMINE FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LTD (IN) | 2018-11-07 | — | — | EP | disclosed |
| EP-3212626-A1 | THREE COMPONENT SALTS OF FUMARIC ACID MONOMETHYL ESTER WITH PIPERAZINE OR ETHYLENE DIAMINE FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2017-09-06 | — | — | EP | disclosed |
| US-9725404-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-9725404-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| US-9725404-B2 | Compositions and methods for the treatment of multiple sclerosis | CELLIX BIO PRIVATE LIMITED (IN) | 2017-08-08 | — | — | US | disclosed |
| WO-2016098119-A1 | THREE COMPONENT SALTS OF FUMARIC ACID MONOMETHYL ESTER WITH PIPERAZINE OR ETHYLENE DIAMINE FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016098119-A1 | THREE COMPONENT SALTS OF FUMARIC ACID MONOMETHYL ESTER WITH PIPERAZINE OR ETHYLENE DIAMINE FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-06-23 | — | — | WO | disclosed |
| US-20160115115-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-28 | — | — | US | disclosed |
| US-20160115115-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-28 | — | — | US | disclosed |
| US-20160115115-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | CELLIX BIO PRIVATE LIMITED (IN) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115115-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS | HLA-DRB1, PMP22, SI | HCAR2 872/4885KEAP1 1652/4885NFE2L2 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.